These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32347983)

  • 1. Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
    Wilson H; Pagano G; de Natale ER; Mansur A; Caminiti SP; Polychronis S; Middleton LT; Price G; Schmidt KF; Gunn RN; Rabiner EA; Politis M
    Mov Disord; 2020 Aug; 35(8):1416-1427. PubMed ID: 32347983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain:
    Mansur A; Rabiner EA; Comley RA; Lewis Y; Middleton LT; Huiban M; Passchier J; Tsukada H; Gunn RN;
    J Nucl Med; 2020 Jan; 61(1):96-103. PubMed ID: 31324712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2022 Sep; 37(9):1883-1892. PubMed ID: 35819412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Synaptic Density in Patients with Lewy Body Dementia: An [
    Andersen KB; Hansen AK; Damholdt MF; Horsager J; Skjaerbaek C; Gottrup H; Klit H; Schacht AC; Danielsen EH; Brooks DJ; Borghammer P
    Mov Disord; 2021 Sep; 36(9):2057-2065. PubMed ID: 33899255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
    Delva A; Van Weehaeghe D; Koole M; Van Laere K; Vandenberghe W
    Mov Disord; 2020 Nov; 35(11):1977-1986. PubMed ID: 32767618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Synaptic Loss in Primary Tauopathies: An In Vivo [
    Holland N; Jones PS; Savulich G; Naessens M; Malpetti M; Whiteside DJ; Street D; Swann P; Hong YT; Fryer TD; Rittman T; Mulroy E; Aigbirhio FI; Bhatia KP; O'Brien JT; Rowe JB
    Mov Disord; 2023 Jul; 38(7):1316-1326. PubMed ID: 37171832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild Motor Signs in Healthy Aging Are Associated with Lower Synaptic Density in the Brain.
    Van Cauwenberge MGA; Delva A; Vande Casteele T; Laroy M; Radwan A; Vansteelandt K; Van den Stock J; Bouckaert F; Van Laere K; Emsell L; Vandenberghe W; Vandenbulcke M
    Mov Disord; 2023 Oct; 38(10):1786-1794. PubMed ID: 37574924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synaptic loss and its association with symptom severity in Parkinson's disease.
    Holmes SE; Honhar P; Tinaz S; Naganawa M; Hilmer AT; Gallezot JD; Dias M; Yang Y; Toyonaga T; Esterlis I; Mecca A; Van Dyck C; Henry S; Ropchan J; Nabulsi N; Louis ED; Comley R; Finnema SJ; Carson RE; Matuskey D
    NPJ Parkinsons Dis; 2024 Feb; 10(1):42. PubMed ID: 38402233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study.
    Delva A; Michiels L; Koole M; Van Laere K; Vandenberghe W
    Neurology; 2022 Jan; 98(1):e83-e94. PubMed ID: 34663644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synaptic Loss in Primary Tauopathies Revealed by [
    Holland N; Jones PS; Savulich G; Wiggins JK; Hong YT; Fryer TD; Manavaki R; Sephton SM; Boros I; Malpetti M; Hezemans FH; Aigbirhio FI; Coles JP; O'Brien J; Rowe JB
    Mov Disord; 2020 Oct; 35(10):1834-1842. PubMed ID: 32652635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [
    Andersen KB; Hansen AK; Schacht AC; Horsager J; Gottrup H; Klit H; Danielsen EH; Poston KL; Pavese N; Brooks DJ; Borghammer P
    Mov Disord; 2023 May; 38(5):796-805. PubMed ID: 36905188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
    Chou KL; Dayalu P; Koeppe RA; Gilman S; Spears CC; Albin RL; Kotagal V
    Mov Disord; 2022 Nov; 37(11):2301-2307. PubMed ID: 36102173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synaptic Density and Neuronal Metabolic Function Measured by Positron Emission Tomography in the Unilateral 6-OHDA Rat Model of Parkinson's Disease.
    Raval NR; Gudmundsen F; Juhl M; Andersen IV; Speth N; Videbæk A; Petersen IN; Mikkelsen JD; Fisher PM; Herth MM; Plavén-Sigray P; Knudsen GM; Palner M
    Front Synaptic Neurosci; 2021; 13():715811. PubMed ID: 34867258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-Year Follow-up of [
    Kogan RV; Janzen A; Meles SK; Sittig E; Renken RJ; Gurvits V; Mayer G; Leenders KL; Oertel WH;
    Mov Disord; 2021 Jan; 36(1):230-235. PubMed ID: 32909650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Kremer T; Taylor KI; Siebourg-Polster J; Gerken T; Staempfli A; Czech C; Dukart J; Galasko D; Foroud T; Chahine LM; Coffey CS; Simuni T; Weintraub D; Seibyl J; Poston KL; Toga AW; Tanner CM; Marek K; Hutten SJ; Dziadek S; Trenkwalder C; Pagano G; Mollenhauer B
    Mov Disord; 2021 Aug; 36(8):1972-1978. PubMed ID: 33942926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.